NCT03192410Active, not recruiting
Prospective Cohort Study of 4,837 Post-myocardial Infarction Patients (Alpha Omega Cohort)
Source: ClinicalTrials.gov · Last updated 19 Aug 2026
Brief summary (registry, in English)
The Alpha Omega Cohort is a prospective study of 4,837 state-of-the-art drug-treated Dutch patients aged 60-80 years who had a clinically diagnosed myocardial infarction up to 10 years before enrolment. During the first 40 months of follow-up, patients took part in an experimental study of low doses n-3 fatty acids (Alpha Omega Trial, ClinicalTrials.gov NCT00127452). At baseline (2002-2006), data on medical history, medication use, diet, lifestyle and other factors were collected by means of questionnaires. Patients were physically examined by trained research nurses and blood samples were obtained. Follow-up for vital status and cause-specific mortality is ongoing. The trial was approved by a central medical ethics committee (Haga Hospital, The Hague, The Netherlands) and all patients provided written informed consent.
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 4837 (actual)
- First submitted
- 10 Jun 2017
- Start date
- 1 Apr 2002
- Primary completion date
- 31 Jan 2040
- Lead sponsor
- Wageningen University
- Diseases
- Coronary artery disease, Type 2 diabetes
- NCT number
- NCT03192410
What you commit to
- Study type: Observational
- Participants enrolled: 4837
- From 1 Apr 2002 to the primary completion date, 31 Jan 2040
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Presence of cancer with \< 1 y of life expectancy
- Cognitive impairment, as indicated by the Mini Mental State Examination (score \<= 21)
Other
- Living in a nursing home or other institution
- Participation in another scientific study
- Habitual margarine intake \< 10 g per day
- Habitual fish intake \> 150 g per day
- Habitual alcohol intake \> 6 drinks per day
- Use of fish oil capsules or other supplements containing omega-3 fatty acids
- Unintended weight loss \> 5 kg in the past year
- Lack of facilities for cooled margarine storage at home
- Inability or unwillingness to comply with study procedures
Who the study is looking for
- Men and women
- Aged 60 through 80 y
- Verified clinically diagnosed myocardial infarction up to 10 y before entry into the study
- Written informed consent
Criteria the registry did not label
- The Alpha Omega Cohort is a prospective cohort study. The cohort originated from the Alpha Omega Trial, a 40-month intervention study of low doses of n-3 fatty acids (in margarine spreads) and cardiovascular events (NCT00127452). The in/exclusion criteria were defined for the Alpha Omega Trial.
Age in the registry: 60 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Wageningen University, Division of Human Nutrition Coordinator of this site? Confirm its status | Wageningen | Netherlands | Unknown status |
Related publications
- Dietary magnesium and risk of cardiovascular and all-cause mortality after myocardial infarction: A prospective analysis in the Alpha Omega Cohort.Front Cardiovasc Med · 2022 · PMID 36035961
- Dietary and Circulating Long-Chain Omega-3 Polyunsaturated Fatty Acids and Mortality Risk After Myocardial Infarction: A Long-Term Follow-Up of the Alpha Omega Cohort.J Am Heart Assoc · 2021 · PMID 34845924
This page is information, not medical advice. Discuss any trial with your doctor.